Industrial Application was Evogene’s largest segment in fiscal 2025, bringing in $2.17M of $3.85M (56%).
| Segment | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Evogene | — | — | — | — | |||||||
| Agriculture | $876.00K | $1.13M | $2.96M | $1.37M | |||||||
| Industrial Application | $72.00K | $1.08M | $2.22M | $2.17M | |||||||
| Industry | — | — | — | — | |||||||
| Human Health | $513.00K | $487.00K | $80.00K | — | |||||||
| Unallocated | $214.00K | $287.00K | $323.00K | $311.00K | |||||||
| Total | $1.68M | $2.98M | $5.58M | $3.85M |
Evogene brought in $3.85M from its three segments in fiscal 2025, the year ended December 31, 2025. Evogene regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $5.58M. Industrial Application was the largest at $2.17M (56.3%), ahead of Agriculture at $1.37M (35.7%) and Unallocated at $311.00K (8.1%).
Compared with fiscal 2024, every segment above 2% of revenue shrank. Industrial Application held up best, down 2.3% to $2.17M, and Agriculture fell the most, down 53.5% to $1.37M.
Evogene stopped reporting Human Health as a separate segment after fiscal 2024, when it brought in $80.00K.
Revenue Recognized At A Point In Time was Evogene’s largest revenue line in fiscal 2025, bringing in $2.52M of $3.85M (65%).
| The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table. | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenue Recognized At A Point In Time | $644.00K | $1.56M | $3.30M | $2.52M |
| Revenue Recognized Over Time | $1.03M | $1.42M | $2.28M | $1.33M |
| Total | $1.68M | $2.98M | $5.58M | $3.85M |
Evogene brought in $3.85M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 30.9% from $5.58M in fiscal 2024. Revenue Recognized At A Point In Time was the largest at $2.52M (65.4%), ahead of Revenue Recognized Over Time at $1.33M (34.6%).
Compared with fiscal 2024, Revenue Recognized At A Point In Time fell 23.6% to $2.52M and Revenue Recognized Over Time fell 41.4% to $1.33M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $1.68M to $3.85M, a compound annual growth rate of 32.0%. Revenue Recognized At A Point In Time's share of the total rose from 38.4% to 65.4%.
Evogene (EVGN) reports its revenue by segment and by the axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.. In fiscal 2025, Industrial Application was its largest segment, bringing in $2.17M (56.3% of the total), followed by Agriculture at $1.37M (35.7%).
Industrial Application was Evogene's largest segment in fiscal 2025, bringing in $2.17M, or 56.3% of the $3.85M total across its three segments.
Revenue Recognized At A Point In Time was Evogene's largest revenue line in fiscal 2025, bringing in $2.52M, or 65.4% of the $3.85M total across its two revenue lines.
Every figure comes from Evogene's annual financial filings, as reported. Each line keeps the name Evogene gives it, and years follow its fiscal calendar.
Evogene's revenue by segment goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.